Edesa Biotech's CEO, Pardeep Nijhawan, bought 50,571 shares on March 2, 2026, for approximately $98,896, alongside a 10,016-share RSU grant, signaling executive confidence following February 24 positive Phase 3 data for paridiprubart showing 27% lower 28-day mortality in ARDS patients. A Zacks Small Cap Research report on March 2 further highlighted these strengthened results, including benefits in non-ventilated patients and subgroups like pneumonia cases. High early volume exceeded 5 million shares, amplifying the move in regular trading hours as traders reacted to the fresh insider activity and reaffirmed trial implications. Based on available reports.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.